Deutsche Bank Reiterates €17.00 Price Target for Evotec (EVT)
Evotec (ETR:EVT) has been given a €17.00 ($20.24) price objective by investment analysts at Deutsche Bank in a report issued on Tuesday. The firm presently has a “buy” rating on the stock. Deutsche Bank’s price objective indicates a potential upside of 31.27% from the stock’s previous close.
Several other analysts also recently issued reports on the company. Berenberg Bank set a €16.00 ($19.05) target price on Evotec and gave the company a “neutral” rating in a research note on Wednesday, November 8th. Oddo Bhf set a €20.00 ($23.81) target price on Evotec and gave the company a “buy” rating in a research note on Thursday, November 9th. Finally, Oddo Securities set a €14.00 ($16.67) target price on Evotec and gave the company a “neutral” rating in a research note on Friday, August 11th.
Evotec (ETR:EVT) traded up €1.06 ($1.26) during midday trading on Tuesday, hitting €12.95 ($15.42). The stock had a trading volume of 2,713,634 shares, compared to its average volume of 3,250,000. Evotec has a 1 year low of €6.08 ($7.24) and a 1 year high of €22.50 ($26.79).
TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/10/deutsche-bank-reiterates-17-00-price-target-for-evotec-evt.html.
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.